Terms: = Leukemia AND NCOR2, SMRTE-tau, 9612, ENSG00000196498, SMRTE, TNRC14, TRAC-1, SMRT, CTG26, TRAC1 AND Treatment
11 results:
1. [Efficacy Analysis of Unrelated Cord Blood Transplantation for High-Risk Refractory AML1-ETO Positive Myeloid leukemia].
Ren JR; Zhu XY; Tang BL; Wan X; Tong J; Zhang L; Zhang XH; Song KD; Yao W; Sun GY; Liu HL; Sun ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1246-1252. PubMed ID: 31418388
[TBL] [Abstract] [Full Text] [Related]
2. [Relative analysis of platelet activation with bleeding risk in patients with primary immune thrombocytopenia].
Lyu ME; Li Y; Lyu CC; Liu WJ; Guan Y; Wang SX; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):33-38. PubMed ID: 28219222
[No Abstract] [Full Text] [Related]
3. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract] [Full Text] [Related]
4. Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.
Wang C; Lu J; Wang Y; Bai S; Wang Y; Wang L; Sheng G
J Biochem Mol Toxicol; 2012 Jan; 26(1):35-43. PubMed ID: 21928377
[TBL] [Abstract] [Full Text] [Related]
5. Coiled-coil domain of PML is essential for the aberrant dynamics of PML-RARalpha, resulting in sequestration and decreased mobility of smrt.
Huang Y; Qiu J; Chen G; Dong S
Biochem Biophys Res Commun; 2008 Jan; 365(2):258-65. PubMed ID: 17991421
[TBL] [Abstract] [Full Text] [Related]
6. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
[TBL] [Abstract] [Full Text] [Related]
7. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
Minucci S; Nervi C; Lo Coco F; Pelicci PG
Oncogene; 2001 May; 20(24):3110-5. PubMed ID: 11420727
[TBL] [Abstract] [Full Text] [Related]
8. Cell signaling switches HOX-PBX complexes from repressors to activators of transcription mediated by histone deacetylases and histone acetyltransferases.
Saleh M; Rambaldi I; Yang XJ; Featherstone MS
Mol Cell Biol; 2000 Nov; 20(22):8623-33. PubMed ID: 11046157
[TBL] [Abstract] [Full Text] [Related]
9. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.
So CW; Dong S; So CK; Cheng GX; Huang QH; Chen SJ; Chan LC
Leukemia; 2000 Jan; 14(1):77-83. PubMed ID: 10637480
[TBL] [Abstract] [Full Text] [Related]
10. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.
David G; Alland L; Hong SH; Wong CW; DePinho RA; Dejean A
Oncogene; 1998 May; 16(19):2549-56. PubMed ID: 9627120
[TBL] [Abstract] [Full Text] [Related]
11. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract] [Full Text] [Related]
